We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Interest in Commercial Applications for Proteomics Continues to Grow

By LabMedica International staff writers
Posted on 15 Oct 2014
Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies.

Proteomics is the study of the structure and function of proteins. This includes the study of which proteins are expressed, when and where they are expressed, and of interactions with proteins and other types of molecules. Many drug targets are proteins, and proteomics is an important tool for identification and characterization of novel drug targets. Furthermore, proteomics is an important tool for the identification of novel biomarkers and biomarker panels for diagnosis of diseases.

Among the significant business connections cited in the recent report “Proteomics Markets for Research and IVD Applications” published by Kalorama Information (New York, NY, USA) were:

Thermo Fisher Scientific (Milford, MA, USA) and Nuclea Biotechnologies (Pittsfield, MA, USA) will develop multiplexed mass spectrometry-based research methods that Nuclea will use to analyze donor plasma samples from Boston-based diabetes research collaborations.

BG Medicine (Waltham, MA, USA) and Kindstar Diagnostics (China) announced an agreement under which Kindstar will offer galectin-3 testing services in China.

Biocartis (Mechelen, Belgium) and Invetech (Melbourne (Australia) announced a collaboration agreement to support development and manufacture of Evalution, Biocartis’ advanced multiplex platform for analysis of a broad range of protein and nucleic acid-based biomarkers. Invetech provides instrument development, custom automation, and contract manufacturing.

“There is a lot of interest in identification and validation of novel biomarkers that may represent potential drug targets or may lead to novel diagnostic tests,” said Bruce Carlson, publisher of Kalorama Information. “Researchers are looking to proteomics for these discoveries.”

Related Links:

Kalorama Information



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Lab Sample Rotator
H5600 Revolver
New
Silver Member
Benchtop Image Acquisition Device
Microwell Imager

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma

New Method Simplifies Preparation of Tumor Genomic DNA Libraries